- Home
- CORT vs EWTX Comparison
CORT vs EWTX Comparison
Compare CORT & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CORT | EWTX |
|---|---|---|
| Founded | 1998 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.3B |
| IPO Year | 2001 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CORT | EWTX |
|---|---|---|
| Price | $32.09 | $29.38 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 8 |
| Target Price | ★ $105.20 | $36.00 |
| AVG Volume (30 Days) | ★ 1.7M | 734.9K |
| Earning Date | 05-25-2026 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.82 | N/A |
| Revenue | ★ $761,407,000.00 | N/A |
| Revenue This Year | $29.97 | N/A |
| Revenue Next Year | $30.25 | N/A |
| P/E Ratio | $39.50 | ★ N/A |
| Revenue Growth | ★ 12.79 | N/A |
| 52 Week Low | $28.66 | $10.60 |
| 52 Week High | $117.33 | $31.82 |
Technical Indicators
Market Signals| Indicator | CORT | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | 29.97 | 51.58 |
| Support Level | $28.66 | $28.56 |
| Resistance Level | $41.92 | $31.12 |
| Average True Range (ATR) | 1.63 | 1.51 |
| MACD | 0.13 | -0.07 |
| Stochastic Oscillator | 3.90 | 53.56 |
Price Performance
Historical ComparisonAbout CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.